Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Nezam Afdhal, K. Rajender Reddy, David R. Nelson, Eric Lawitz, Stuart C. Gordon, Eugene Schiff, Ronald Nahass, Reem Ghalib, Norman Gitlin, Robert Herring, Jacob Lalezari, Ziad H. Younes, Paul J. Pockros, Adrian M. Di Bisceglie, Sanjeev Arora, G. Mani Subramanian, Yanni Zhu, Hadas Dvory-Sobol, Jenny C. Yang, Phillip S. PangWilliam T. Symonds, John G. McHutchison, Andrew J. Muir, Mark Sulkowski, Paul Kwo

Research output: Contribution to journalArticlepeer-review

1072 Scopus citations

Abstract

BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. METHODS: We conducted a phase 3, randomized, open-label study involving patients infected with HCV genotype 1 who had not had a sustained virologic response after treatment with peginterferon and ribavirin, with or without a protease inhibitor. Patients were randomly assigned to receive the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofosbuvir in a once-daily, fixed-dose combination tablet for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Among the 440 patients who underwent randomization and were treated, 20% had cirrhosis and 79% had HCV genotype 1a infection. The rates of sustained virologic response were high in all treatment groups: 94% (95% confidence interval [CI], 87 to 97) in the group that received 12 weeks of ledipasvir-sofosbuvir; 96% (95% CI, 91 to 99) in the group that received 12 weeks of ledipasvir-sofosbuvir and ribavirin; 99% (95% CI, 95 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 95 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir and ribavirin. No patient discontinued treatment owing to an adverse event. The most common adverse events were fatigue, headache, and nausea. CONCLUSIONS: Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologic response to prior interferon-based treatment.

Original languageEnglish (US)
Pages (from-to)1483-1493
Number of pages11
JournalNew England Journal of Medicine
Volume370
Issue number16
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection'. Together they form a unique fingerprint.

Cite this